Advertisement

Antianämika

  • Klaus Mengel
  • Harald Schmidt

Zusammenfassung

Die Verordnungen der Antianämika erstrecken sich auf Eisenpräparate, Folsäure, Folsäurekombinationen und Epoetinpräparate.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American Medical Association (1986): Drug evaluations (6th Edition). Saunders Company Philadelphia, London, pp. 589–601.Google Scholar
  2. Arzneimittelbrief (2002): Arzneitherapien an der Obergrenze der finanziellen Belastbarkeit (Teil 1). Beispiele Erythropoietin und i.v. Immunglobuline in der Hämatologie/Onkologie. 36: 25–29.Google Scholar
  3. Arzneimittelbrief (2003): Wirksamkeit von rekombinantem Erythropoitin (rhEPO) bei schwerkranken Patienten auf Intensivstationen.: 37:29–30.Google Scholar
  4. Arzneimittel-Richtlinien (2002): Epoetin zur Behandlung der Anämie bei Patienten mit soliden Tumoren, malignen Lymphomen und Plasmozytom (z. B. Erypo; NeoRecormon). Dtsch Ärztebl 99: C2129–C2130.Google Scholar
  5. Baker WF, Bick RL (1999): Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 25: 387–406.PubMedCrossRefGoogle Scholar
  6. Bamonti-Catena F, Buccianti G, Porcella A, Valenti G, Como G et al (1999): Folate measurements in patients on regular hemodalysis treatment. Am J Kidney Dis 33:492–497.PubMedCrossRefGoogle Scholar
  7. Begemann H, Rastetter J (Hrsg) (1993): Klinische Hämatologie, Kapitel „Anämien“. Georg-Thieme-Verlag Stuttgart, New York, S. 237–418.Google Scholar
  8. Besarab A, Bolton WK, Browne JK, Egrie, JC, Nissenson AR et al (1998): The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590.PubMedCrossRefGoogle Scholar
  9. Büchner T (2003): Anämien. In: Therapie Innerer Krankheiten (Hrsg Paumgartner G, Steinbeck G). Springer-Verlag Berlin, Heidelberg, New York, 10. Aufl., S. 1015.Google Scholar
  10. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J et al (2002): Pure red-cell aplasia and antierythropietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475.PubMedCrossRefGoogle Scholar
  11. Collins AJ, Ma JZ, Xia A, Ebben J (1998): Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32(Suppl 4): S133–S141.PubMedCrossRefGoogle Scholar
  12. Czeisel AE, Dudas I (1992): Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832–1835.CrossRefGoogle Scholar
  13. Dührsen U (2002): Gibt es Indikationen für Erythropoetin in der Onkologie? Dtsch Ärztebl 99: A3470–A3475.Google Scholar
  14. Eckardt KU (1998): Erythropoietin, Karriere eines Hormons. Dtsch Ärztebl 95: A-285–290.Google Scholar
  15. Eckardt KU, Casadevall N (2003): Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18: 865–869.PubMedCrossRefGoogle Scholar
  16. Fishbane S, Mittal SK, Maesaka JK (1999): Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55: 67–70.CrossRefGoogle Scholar
  17. Forth W, Rummel W, Wollenberg P (2001): Pharmakotherapie des Eisenmangels. In: Allgemeine und spezielle Pharmakologie und Toxikologie (Hrsg Forth W, Henschler D, Rummel W, Förstermann U, Starke K). Urban & Fischer Verlag München, Jena, 8. Aufl., S. 739–749.Google Scholar
  18. Hanley DF (2004): The challenge of stroke prevention. JAMA 291: 621–622.PubMedCrossRefGoogle Scholar
  19. Heinrich HC (1986): Bioverfügbarkeit und therapeutischer Wert oraler Eisen(II)-und Eisen(III)-Präparate. Dtsch Apoth Ztg 126: 681–690.Google Scholar
  20. Homocysteine Studies Collaboration (2002): Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022.CrossRefGoogle Scholar
  21. Ibbotson T, Goa KL (2001): Darbepoetin alfa. Drugs 61:2097–2104.PubMedCrossRefGoogle Scholar
  22. Kaltwasser JP (2003): Eisenmangelanämie. In: Berdel WE, Böhm M, Classen M, Diehl V, Kochsiek K, Schmigel W (Hrsg): Innere Medizin. 5. Auflage, Urban & Fischer, München Jena, S. 706–711.Google Scholar
  23. Kaltwasser JP, Werner E, Niechzial M (1987): Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneim Forsch 37:122–129.Google Scholar
  24. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG et al (1998): Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339: 578–583.PubMedCrossRefGoogle Scholar
  25. Koletzko B, Pietrzik K (2004): Gesundheitliche Bedeutung der Folsäure. Dtsch Ärztebl 101: A 1670–1681.Google Scholar
  26. Lange H, Suryapranata H, De Luca G, Böner C, Dille J et al (2004): Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: 2673–2681.PubMedCrossRefGoogle Scholar
  27. MacDougall IC (1999): Strategies for iron supplementation: Oral versus intravenous. Kidney Int 55: 61–66.CrossRefGoogle Scholar
  28. Marcus R, Coulston AM (1996): The Vitamins. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 9th edition. McGraw-Hill, New York, pp. 1547–1553.Google Scholar
  29. Marsh WA, Rascati KL (1999): Meta-analyses of the effectiveness of erythropoetin for end-stage renal disease and cancer. Clin Ther 21:1443–1455.PubMedCrossRefGoogle Scholar
  30. O’Riordan E, Foley RN (2001): When should we start erythropoietin therapy? Nephrol Dial Transplant 16:891–892.CrossRefGoogle Scholar
  31. Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL et al (2004): Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 350:134–142.PubMedCrossRefGoogle Scholar
  32. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL et al (2001): Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204–1214.PubMedCrossRefGoogle Scholar
  33. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC et al (2004): Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarktion, and death: the vitamin intervention for stroke prevention (VISP). JAMA 291: 565–575.PubMedCrossRefGoogle Scholar
  34. Wald NJ (2004): Folic acid and the prevention of neural-tube defects. N Engl J Med 350:101–103.PubMedCrossRefGoogle Scholar
  35. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000): The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin ß: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15: 2014–2019.PubMedCrossRefGoogle Scholar
  36. Wooltorton E (2002): Epoetin alfa (Eprex): reports of pure red cell aplasia. Can Med Assoc J 166: 480.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Klaus Mengel
    • 1
  • Harald Schmidt
    • 2
  1. 1.Mannheim
  2. 2.Rudolf-Buchheim-Institut für PharmakologieGießen

Personalised recommendations